AMGN · 10-Q · 2026Q3 · Full report

XGEVA Biosimilar Competition

AMGEN INC · 2026-11-04 · Importance 78 · Surprise 74

Global XGEVA sales decreased 47% in the third quarter and 36% in the first nine months of 2026 as multiple biosimilars launched in the U.S. and ROW. Nine-month sales fell to $1.051 billion from $1.637 billion. The declines were primarily driven by lower volume of 32% for the quarter and 24% for the nine-month period, along with lower net selling prices of 11% and 10%, respectively. Amgen expected continued sales erosion through the remainder of 2026 due to increased competition.

Key facts

• Amgen filed supplemental complaints on October 2 and October 5, 2026, asserting infringement of U.S. Patent No. 12,679,865 in its actions against Dr. Reddy’s Laboratories and Alkem Laboratories, respectively. source
• Global XGEVA sales decreased 47% in the three months and 36% in the nine months ended September 30, 2026, as multiple biosimilars launched in the United States and ROW. source
• Global XGEVA sales decreases in the three and nine months ended September 30, 2026 were primarily driven by lower volume of 32% and 24%, respectively, and lower net selling price of 11% and 10%, respectively. source
• Amgen expects continued XGEVA sales erosion for the remainder of 2026 due to increased competition from multiple biosimilars launched in the United States and ROW. source